PT1198479E - Imunoconjugados direccionados para alvos neovasculares - Google Patents

Imunoconjugados direccionados para alvos neovasculares Download PDF

Info

Publication number
PT1198479E
PT1198479E PT00941443T PT00941443T PT1198479E PT 1198479 E PT1198479 E PT 1198479E PT 00941443 T PT00941443 T PT 00941443T PT 00941443 T PT00941443 T PT 00941443T PT 1198479 E PT1198479 E PT 1198479E
Authority
PT
Portugal
Prior art keywords
immunoconjugates
alanine
factor vii
effector domain
neovascular
Prior art date
Application number
PT00941443T
Other languages
English (en)
Inventor
Alan Garen
Zhiwei Hu
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of PT1198479E publication Critical patent/PT1198479E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
PT00941443T 1999-07-01 2000-06-14 Imunoconjugados direccionados para alvos neovasculares PT1198479E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14216199P 1999-07-01 1999-07-01

Publications (1)

Publication Number Publication Date
PT1198479E true PT1198479E (pt) 2008-08-12

Family

ID=22498780

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00941443T PT1198479E (pt) 1999-07-01 2000-06-14 Imunoconjugados direccionados para alvos neovasculares

Country Status (11)

Country Link
EP (1) EP1198479B1 (pt)
JP (2) JP2003504315A (pt)
AT (1) ATE398633T1 (pt)
AU (1) AU775621B2 (pt)
CA (1) CA2377381C (pt)
CY (1) CY1110394T1 (pt)
DE (1) DE60039240D1 (pt)
DK (1) DK1198479T3 (pt)
ES (1) ES2307517T3 (pt)
PT (1) PT1198479E (pt)
WO (1) WO2001002439A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
AU2003208839A1 (en) 2002-02-13 2003-09-04 Micromet Ag De-immunized (poly)peptide constructs
US20060229239A9 (en) * 2002-03-08 2006-10-12 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
AU2003214023A1 (en) * 2002-03-12 2003-09-22 Novo Nordisk A/S Dimeric tf antagonist comprising two factor vii polypeptides
AU2003242506A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S Tf antagonist
EP1523504A2 (en) * 2002-07-12 2005-04-20 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2012203896B2 (en) * 2003-05-06 2014-09-25 Bioverativ Therapeutics Inc. Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
DK2298347T3 (en) 2003-05-06 2016-01-11 Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
EP1684790A4 (en) * 2003-11-18 2008-04-30 Iconic Therapeutics Inc HOMOGENEOUS PREPARATIONS OF CHIMERIC PROTEINS
JP2009203161A (ja) * 2006-06-05 2009-09-10 Mebiopharm Co Ltd リウマチ治療薬
EP2591006B1 (en) 2010-07-09 2019-04-24 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
ES2856968T3 (es) 2016-01-15 2021-09-28 Rigshospitalet Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
WO2017181145A1 (en) * 2016-04-14 2017-10-19 Iconic Therapeutics, Inc. Compositions and methods for treating disorders associated with νeοvascularization
MA46864A (fr) 2016-11-17 2021-04-28 Minerva Imaging Aps Facteur vii inhibé par le site actif marqué par 177-lu
AU2018235945A1 (en) 2017-03-14 2019-10-17 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates
AU2018341227A1 (en) * 2017-09-27 2020-04-09 Ohio State Innovation Foundation Tissue factor-targeting CAR-NK and CAR-T cell therapy
US20210069306A1 (en) * 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
HU220347B (hu) * 1994-07-11 2001-12-28 Board Of Regents The University Of Texas System Készítmény az érrendszer specifikus koagulálásához
ATE244579T1 (de) * 1997-01-22 2003-07-15 Univ Texas Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren

Also Published As

Publication number Publication date
ATE398633T1 (de) 2008-07-15
JP5745486B2 (ja) 2015-07-08
EP1198479A1 (en) 2002-04-24
EP1198479B1 (en) 2008-06-18
AU775621B2 (en) 2004-08-05
CY1110394T1 (el) 2015-04-29
JP2003504315A (ja) 2003-02-04
CA2377381C (en) 2013-06-11
DE60039240D1 (de) 2008-07-31
JP2012255032A (ja) 2012-12-27
AU5614900A (en) 2001-01-22
CA2377381A1 (en) 2001-01-11
DK1198479T3 (da) 2008-10-13
ES2307517T3 (es) 2008-12-01
EP1198479A4 (en) 2004-10-20
WO2001002439A1 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
CY1110394T1 (el) Ανοσοσυζευγματα νεοαγγειακης στοχευσης
AU665360B2 (en) Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
ES2224099T3 (es) Inmunotoxinas dirigidas contra antigenos de superficies relacionados con c-erbb-2 (her-2/neu).
MY111196A (en) Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
WO2004032828A3 (en) Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
SA112330402B1 (ar) اتحادات جسم مضاد- عقار
DE69934337D1 (de) Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
EP2841103A1 (en) Dr5 ligand drug conjugates
DE69530109D1 (de) Zusammensetzung für behandlung von maligner tumore und ihre metastase
Muñoz et al. In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours
US20230110128A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
NZ335353A (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
CA2366713A1 (en) Antibody and chemokine constructs and their use in the treatment of autoimmune diseases
AU2001261987A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
MX2023000499A (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular.
EP0802799A1 (en) BIOTHERAPY OF CANCER BY TARGETING TP-3/p80
Rathore et al. Generation of active immunotoxins containing recombinant restrictocin
Lechleider et al. Advances in the development of anti-CD22 immunotoxins containing Pseudomonas exotoxin for treatment of hematologic malignancies
WO2004007557A3 (en) Tf antagonist
WO1997041895A3 (en) TREATMENT OF ASTHMA WITH TNFR-Ig
JPH09500869A (ja) トキシンの治療的使用に対する副作用および非感受性を防ぐ方法
WO1990011779A1 (en) Heteroconjugates
Ng et al. Cancer-homing toxins